BioXcel Therapeutics Inc
(FRA:BX2)
€
0.5724
0.0254 (4.64%)
Market Cap: 25.17 Mil
Enterprise Value: 68.70 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 18/100 
BioXcel Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 09, 2021 / 03:40PM GMT
Release Date Price:
€30.12
(+0.77%)
Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst
Okay. Good afternoon, everyone, and welcome to the 4:40 p.m. session here on day 2 at the Goldman Sachs Global Healthcare Conference. My name is Graig Suvannavejh. I cover U.S. and European biopharma names here at the firm. It's my great pleasure to be hosting BioXcel Therapeutics in a fireside chat. And with that, joining from the company are CEO, Vimal Mehta; and Chief Commercialization Officer; William Kane. Gentlemen, it's good to see you both, and welcome.
Vimal D. Mehta
BioXcel Therapeutics, Inc. - Founder, CEO, President, & Director
Thank you, Graig.
William P. Kane
BioXcel Therapeutics, Inc. - Executive VP & Chief Commercial Officer
Thank you, Graig.
Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst
Okay, very well. Well, my sense is there's probably a number of
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers